KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Shares Outstanding

Last Annual Value

15.27M

3-Year CAGR

66%

5-Year CAGR

67%

10-Year CAGR

29%

KT

Kalaris Therapeutics Inc Competitors Analysis of shares-outstanding

KLRS · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
15.27M
50.0%41.1%N/A 
73.74M
1.5%1.6%14.2%
24.44M
1.6%6.8%N/A
69.58M
17.8%10.6%N/A
95.19M
81.3%101.9%N/A
37.25M
-0.2%44.4%N/A
19.78M
-30.1%-27.4%-5.9%
53.66M
7.7%5.9%N/A
75.82M
16.8%9.8%N/A
766.60K
15.3%4.8%N/A
42.42M
1.5%8.3%12.9%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7